Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Pathward extends TabaPay partnership through 2031

Pathward extends TabaPay partnership through 2031

ReutersReuters2026/08/05 03:01
  • Pathward Financial extended its partnership with money movement platform TabaPay through 2031, expanding program offerings.
  • Agreement adds lending disbursements, cross-border money movement, preferred account funding, targeting faster payments across new use cases.
  • Collaboration supports rapid bi-directional flows via ACH, push-to-card, acquiring, covering loan funding, repayments, account transfers.
  • Expanded routing adds PULSE Disbursements for push payments to Discover Network-branded cards, alongside Mastercard Move and Visa Direct.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pathward Financial Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage